Prostate-cancer mortality at 11 years of follow-up.

ABSTRACT:

Background

Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up.

Methods

The study involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered such screening. The primary outcome was mortality from prostate cancer.

Results

After a median follow-up of 11 years in the core age gro

SUBMITTER: Schroder FH 

PROVIDER: S-EPMC6027585 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature